Biopharma’s Winners And Losers Of 2023: Obesity Drugs Reshape Big Pharma
Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.
Novo Nordisk and Eli Lilly kickstarted an obesity drug revolution in 2023, just as investors cooled on biopharma’s vaccine saviors as the world looked to move on from COVID-19.